CA2308765C - Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation - Google Patents

Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation Download PDF

Info

Publication number
CA2308765C
CA2308765C CA2308765A CA2308765A CA2308765C CA 2308765 C CA2308765 C CA 2308765C CA 2308765 A CA2308765 A CA 2308765A CA 2308765 A CA2308765 A CA 2308765A CA 2308765 C CA2308765 C CA 2308765C
Authority
CA
Canada
Prior art keywords
protein
cells
fragment
immune response
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2308765A
Other languages
English (en)
Other versions
CA2308765A1 (fr
Inventor
Reginald M. Gorczynski
David A. Clark
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trillium Therapeutics ULC
Original Assignee
Trillium Therapeutics ULC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22058127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2308765(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Trillium Therapeutics ULC filed Critical Trillium Therapeutics ULC
Publication of CA2308765A1 publication Critical patent/CA2308765A1/fr
Application granted granted Critical
Publication of CA2308765C publication Critical patent/CA2308765C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)

Abstract

Cette invention concerne des procédés et des compositions permettant d'induire une immunodépression. Ces procédés consistent à administrer une dose efficace de protéine OX-2 ou un acide nucléique codant pour une protéine OX-2. Ils conviennent particulièrement pour prévenir les rejets de greffes, les pertes fotales ainsi que les maladies auto-immunes et les allergies. L'invention porte également sur des techniques et des compositions permettant d'éviter une immunosuppression. Ces procédés comportent l'administration d'une dose efficace d'un agent inhibant la protéine OX-2.
CA2308765A 1997-11-07 1998-11-06 Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation Expired - Fee Related CA2308765C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6476497P 1997-11-07 1997-11-07
US60/064,764 1997-11-07
PCT/CA1998/001038 WO1999024565A1 (fr) 1997-11-07 1998-11-06 Procedes et compositions pour immunomodulation

Publications (2)

Publication Number Publication Date
CA2308765A1 CA2308765A1 (fr) 1999-05-20
CA2308765C true CA2308765C (fr) 2010-10-12

Family

ID=22058127

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2308765A Expired - Fee Related CA2308765C (fr) 1997-11-07 1998-11-06 Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation

Country Status (13)

Country Link
US (6) US6338851B1 (fr)
EP (1) EP1032662B1 (fr)
JP (2) JP4584447B2 (fr)
AT (1) ATE319825T1 (fr)
AU (1) AU748587B2 (fr)
CA (1) CA2308765C (fr)
CY (1) CY1105364T1 (fr)
DE (1) DE69833779T2 (fr)
DK (1) DK1032662T3 (fr)
ES (1) ES2260852T3 (fr)
HK (1) HK1030625A1 (fr)
PT (1) PT1032662E (fr)
WO (1) WO1999024565A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1032662T3 (da) 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
MXPA01010480A (es) * 1999-04-13 2002-03-27 Schering Corp Usos novedosos de la proteina 0x2 de mamifero y reactivos relacionados.
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
US6613327B1 (en) * 1999-07-28 2003-09-02 Genetics Institute, Inc. Methods of preventing immune-mediated abortion by inhibiting a CD28-mediated costimulatory signal
CA2403393A1 (fr) * 2000-03-17 2001-09-20 Reginald M. Gorczynski Techniques et compositions relatifs a l'immunoregulation
EP1283719B1 (fr) * 2000-04-22 2007-09-05 PharmedArtis GmbH Agent apoptotique
CA2417874C (fr) * 2000-08-03 2012-10-02 Transplantation Technologies Inc. Utilisation des inhibiteurs ox-2 pour le traitement du cancer
AUPR069500A0 (en) 2000-10-11 2000-11-09 Coster, Douglas John Tissue modification
AU2333802A (en) * 2000-11-22 2002-06-03 Transplantation Technologies I Truncated cd200
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) * 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (fr) 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Lignee cellulaire de la leucemie lymphoide chronique
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US6906237B2 (en) * 2001-02-27 2005-06-14 G. Scott Herron Vivo assay for anti angiogenic compounds
US7285631B2 (en) 2001-08-10 2007-10-23 Serono Genetics Institute S.A. Human cDNAs and proteins and uses thereof
US20030077282A1 (en) * 2001-10-12 2003-04-24 Bigler Michael Eric Use of bispecific antibodies to regulate immune responses
US7196243B2 (en) 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US20040213783A1 (en) * 2002-12-27 2004-10-28 Janet Liversidge Methods of inducing and maintaining immune tolerance
WO2006099421A2 (fr) 2005-03-14 2006-09-21 The Board Of Trustees Of The Leland Stanford Junior University Procedes et compositions permettant d'evaluer la survie d'un greffon chez un destinataire d'une transplantation d'organe solide
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
GB0506721D0 (en) * 2005-04-01 2005-05-11 Univ Glasgow Soluble immunoregulatory factor
US8075884B2 (en) 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
US20100178652A1 (en) * 2007-01-05 2010-07-15 Litherland Sally A Materials and Methods for the Detection, Prevention and Treatment of Autoimmune Disease
BRPI0814645A2 (pt) 2007-07-25 2015-01-27 Alexion Pharma Inc Métodos e composições para tratar de doença autoimune.
US8252285B2 (en) * 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
US9938579B2 (en) * 2009-01-15 2018-04-10 The Board Of Trustees Of The Leland Stanford Junior University Biomarker panel for diagnosis and prediction of graft rejection
EP3185013B1 (fr) 2009-12-02 2019-10-09 The Board of Trustees of the Leland Stanford Junior University Biomarqueurs pour déterminer un xénotype tolérant à l'allogreffe
JP6012473B2 (ja) 2010-01-11 2016-10-25 アレクシオン ファーマシューティカルズ， インコーポレイテッド 抗ｃｄ２００抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
AU2011215750A1 (en) 2010-02-11 2012-08-23 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-CD200 antibodies
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
WO2012125182A1 (fr) 2011-03-11 2012-09-20 Synageva Biopharma Corp Protéines hybrides npp1
WO2011119980A1 (fr) 2010-03-25 2011-09-29 The Board Of Trustees Of The Leland Stanford Junior University Biomarqueurs protéiques et génétiques pour le rejet de greffes d'organes
EP2723380B1 (fr) 2011-06-24 2019-08-21 Stephen D. Gillies Protéines hybrides d'immunoglobuline à chaîne légère et leurs procédés d'utilisation
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
ES2899895T3 (es) 2014-12-19 2022-03-15 Inozyme Pharma Inc Procedimientos de tratamiento de calcificación tisular
JP6902185B2 (ja) * 2015-11-03 2021-07-14 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Ｃｄ２００阻害剤及びその使用方法
GB201608197D0 (en) * 2016-05-10 2016-06-22 Ducentis Biotherapeutics Ltd Novel proteins
EP3471747A1 (fr) 2016-06-16 2019-04-24 Alexion Pharmaceuticals, Inc. Méthodes de traitement d'une prolifération myo-intimale
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
WO2019067502A1 (fr) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Méthodes d'amélioration de la fonction cardio-vasculaire et de traitement d'une maladie cardio-vasculaire à l'aide d'une ecto-nucléotide pyrophosphatase/phosphodiestérase recombinante
WO2019084682A1 (fr) 2017-10-30 2019-05-09 Mcmaster University Méthodes pour le diagnostic et le traitement de l'endométriose
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
GB9505653D0 (en) * 1995-03-21 1995-05-10 Shober Wharton Method of pest control
WO1997021450A1 (fr) * 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Molecule costimulante ox-2
DK0892643T4 (da) * 1996-03-20 2009-12-14 Bristol Myers Squibb Co Fremgangsmåder til inhibering af et immunrespons ved blokering af GP39/CD40- og CTLA4/CD28/B7-banerne og præparater til anvendelse derved
DK1032662T3 (da) * 1997-11-07 2006-07-03 Trillium Therapeutics Inc Fremgangsmåder og sammensætninger til immunmodulation
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
CA2403393A1 (fr) 2000-03-17 2001-09-20 Reginald M. Gorczynski Techniques et compositions relatifs a l'immunoregulation
AU2333802A (en) 2000-11-22 2002-06-03 Transplantation Technologies I Truncated cd200
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
US7196243B2 (en) * 2002-04-03 2007-03-27 Trillium Therapeutics Inc. Transgenic animal containing CD200 and uses therefor
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery

Also Published As

Publication number Publication date
US20020086011A1 (en) 2002-07-04
EP1032662A1 (fr) 2000-09-06
DE69833779T2 (de) 2006-11-30
US6749854B2 (en) 2004-06-15
WO1999024565A1 (fr) 1999-05-20
CY1105364T1 (el) 2010-03-03
ATE319825T1 (de) 2006-03-15
US6984625B2 (en) 2006-01-10
US7902151B2 (en) 2011-03-08
US20020151485A1 (en) 2002-10-17
PT1032662E (pt) 2006-07-31
US20110206668A1 (en) 2011-08-25
JP4584447B2 (ja) 2010-11-24
DE69833779D1 (de) 2006-05-04
CA2308765A1 (fr) 1999-05-20
US6652858B2 (en) 2003-11-25
US20090232825A1 (en) 2009-09-17
HK1030625A1 (en) 2001-05-11
US6338851B1 (en) 2002-01-15
JP2010155846A (ja) 2010-07-15
DK1032662T3 (da) 2006-07-03
AU1017399A (en) 1999-05-31
US20020103151A1 (en) 2002-08-01
AU748587B2 (en) 2002-06-06
ES2260852T3 (es) 2006-11-01
EP1032662B1 (fr) 2006-03-08
JP2001522867A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
CA2308765C (fr) Utilisation d'une proteine ox-2 ou d'un acide nucleique a des fins d'immunomodulation
US8187598B2 (en) Methods of treating cancer by administering antibodies to CD200
US7553811B2 (en) Methods and compositions for modulating immunity
US7368535B2 (en) CD200 receptors
JP3520272B2 (ja) リンパ球機能関連抗原３のｃｄ２結合ドメイン
JPH09500788A (ja) Ｂ７−２：ｃｔｌａ４／ｃｄ２８カウンターレセプター
EP1337560B1 (fr) Cd200 tronquee
CA2292415A1 (fr) Molecules de liaison avec b7 destinees au traitement d'affections immunitaires
AU2002223338A1 (en) Truncated CD200

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20141106